PX91 Stock Overview
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cassava Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.75 |
| 52 Week High | US$38.00 |
| 52 Week Low | US$3.19 |
| Beta | -0.58 |
| 11 Month Change | -85.22% |
| 3 Month Change | -85.38% |
| 1 Year Change | -80.56% |
| 33 Year Change | -91.87% |
| 5 Year Change | 140.26% |
| Change since IPO | -97.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| PX91 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -85.7% | -0.3% | 0.8% |
| 1Y | -80.6% | -18.3% | 8.6% |
Return vs Industry: PX91 underperformed the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: PX91 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| PX91 volatility | |
|---|---|
| PX91 Average Weekly Movement | 26.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PX91's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PX91's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 29 | Rick Barry | www.cassavasciences.com |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. Fundamentals Summary
| PX91 fundamental statistics | |
|---|---|
| Market cap | €197.13m |
| Earnings (TTM) | -€16.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.7x
P/E RatioIs PX91 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PX91 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.84m |
| Gross Profit | -US$67.84m |
| Other Expenses | -US$50.17m |
| Earnings | -US$17.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PX91 perform over the long term?
See historical performance and comparison